Although no statistically significant difference was observed between the groups, improvement rates in CP score, CP class, and reversal from decompensated to compensated cirrhosis tended to be higher in the CD34+ cell group than in the SOC group at 24 weeks post-enrollment for the FAS (Tables S2–4). The gene discussed is CD34; the disease is Cirrhosis.